Quantum Healthcare Limited FY2025 Results: Financial Analysis and Investor Takeaways

Quantum Healthcare Limited released its unaudited condensed interim financial statements for the fourth quarter and full year ended 31 December 2025. The report provides a detailed look at the Group’s performance, financial health, and operational activities. Below, we distill the key insights, trends, and implications for investors.

Key Financial Metrics

*Q3 2025 and QoQ changes are inferred by dividing H2 results by two, as quarterly breakdowns are not fully disclosed.

Full Year Comparison

Performance Trends and Notable Items

• Revenue Growth: Revenue grew 3.0% YoY to S\$13.1m, driven by the opening of a new dental clinic (TDH Sengkang) in July 2024.
• Profitability: Despite revenue growth, net loss widened to S\$2.9m from S\$2.6m, mainly due to a substantial impairment loss on goodwill (S\$2.2m).
• Gross Margin: Gross profit margin improved modestly, with administrative expenses down 6.2% YoY due to lower staff costs and professional fees, but offset by higher depreciation from new clinic leases.
• Cash Flow: Positive cash flow from operations (S\$2.0m) was reported, and cash balance increased to S\$2.7m (from S\$386k).
• Balance Sheet: Group remains in a net liability position (negative equity of S\$1.05m), improved from negative S\$2.98m a year ago. Working capital remains negative at S\$4.3m, but the company highlights supportive measures from major shareholders and positive operational cash flow.
• Going Concern: Auditor issued a disclaimer of opinion for FY2024; management continues to use the going concern basis, relying on shareholder support, positive cash flow, and no immediate requirement to settle certain large payables.
• Legal Proceedings: The Group resolved a material arbitration and legal dispute with InnoRa GmbH, resulting in a one-off provision for milestone payment and fees (S\$708k + S\$163k), but no further significant provisions are required as of FY2025.
• Fundraising and Dilution: In September 2025, the company completed a S\$3.0m share placement, with S\$563k used for working capital and S\$2m earmarked for acquisitions. Issued share capital rose from 8.0bn to 12.6bn shares, leading to dilution for existing shareholders.
• Dividends: No dividend declared for FY2025 or FY2024, reflecting ongoing losses and focus on cash preservation.
• Segmental Performance: Healthcare (dental) is now the core revenue driver; Vascular business is discontinued but still generates minor legacy costs.

Chairman’s Statement & Tone

“The industry in which the Group operates continues to experience steady demand, while operating cost pressures and manpower constraints persist. Barring any unforeseen circumstances, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next 12 months. The Company continues to actively explore various strategic options, fund raising opportunities and is continuously looking to grow its dental business.”

Commentary: The tone is cautiously optimistic regarding industry demand but acknowledges operational challenges and the need for ongoing capital raising and cost management.

Divestments, Fundraising, and Other Corporate Actions

• Fundraising: September 2025 share placement raised S\$3.0m; S\$2.4m remains unutilized and earmarked for acquisitions, primarily within MedTech.
• Subsidiary Changes: Dormant subsidiaries in Singapore and Malaysia were struck off in FY2025; no material impact on earnings or net assets.
• Debt Settlement: Related party loan was settled via share issuance, reducing loan liabilities but increasing dilution.

Outlook and Forecasted Events

• Industry operating environment is stable, but cost pressures and manpower constraints remain.
• No significant known risks or macro factors are expected to impact performance in the next 12 months, barring unforeseen circumstances.
• The Group is exploring new business opportunities and further fundraising to support expansion.

Conclusion & Investment Recommendations

Overall Assessment: Quantum Healthcare Limited continues to deliver steady top-line growth in its healthcare (dental) business. However, it remains loss-making, with widening net losses due to significant one-off impairment and legal expenses. The balance sheet, while improved, remains in a net liability position, and negative working capital persists. The company’s ability to continue as a going concern is dependent on ongoing shareholder support, successful fundraising, and cost containment.

For Existing Shareholders: Hold with caution. The company is operationally cash flow positive and has managed to raise funds, but ongoing losses and the risk of further dilution through future placements remain. Monitor closely for successful execution of new acquisitions or turnaround in profitability before increasing exposure.

For Potential Investors (Not Currently Holding): Wait and observe. The risk/reward is not compelling given the negative equity, ongoing losses, and reliance on external fundraising and shareholder support. Consider entry only if there is clear evidence of sustainable profitability, balance sheet repair, or value-accretive M&A.

Disclaimer: This analysis is based solely on information disclosed in the company’s FY2025 financial statements. It does not constitute investment advice. All investors should conduct their own due diligence or seek professional advice tailored to their individual circumstances before making investment decisions.

View Quantum Health Historical chart here